[Theranostics in prostate cancer]

Development of radiochemistry and hybrid technology resulted in a new era in the management of prostate cancer. Choline PET provides more sensitive and accurate diagnosis, and it can support the personalized, metastases-directed therapies. PSMA radioligands are used as theranostics worldwide but are not available in Hungary. 68Ga- or 18F-labelled molecules are excellent diagnostic agents which can detect the primary process and its metastases more sensitively than choline, especially at lower PSA levels. 177Lu-labelled PSMA ligand as a therapeutic pair of the diagnostic molecules can provide an effective therapeutic option in metastatic castration resistant prostate cancer. In this publication we review PSMA radioligand therapy (PRLT) in management of prostate cancer based on the recently published European guideline.